Related Experiment Video
Updated: Nov 10, 2025
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
Laia Castells-Roca1,2,3, Eudald Tejero4, Benjamín Rodríguez-Santiago2,5
1Genome Instability and DNA Repair Syndromes Group, Sant Pau Biomedical Research Institute (IIB Sant Pau) and Join Unit UAB-IR Sant Pau on Genomic Medicine, 08041 Barcelona, Spain.
Abstract:
Cancer is a complex disease resulting from the accumulation of genetic dysfunctions. Tumor heterogeneity causes the molecular variety that divergently controls responses to chemotherapy, leading to the recurrent problem of cancer reappearance. For many decades, efforts have focused on identifying essential tumoral genes and cancer driver mutations. More recently, prompted by the clinical success of the synthetic lethality (SL)-based therapy of the PARP inhibitors in homologous recombinant deficient tumors, scientists have centered their novel research on SL interactions (SLI). The state of the art to find new genetic interactions are currently large-scale forward genetic CRISPR screens. CRISPR technology has rapidly evolved to be a common tool in the vast majority of laboratories, as tools to implement CRISPR screen protocols are available to all researchers. Taking advantage of SLI, combinatorial therapies have become the ultimate model to treat cancer with lower toxicity, and therefore better efficiency. This review explores the CRISPR screen methodology, integrates the up-to-date published findings on CRISPR screens in the cancer field and proposes future directions to uncover cancer regulation and individual responses to chemotherapy.
Insights
CRISPR screens identify synthetic lethality interactions (SLI) to improve cancer therapies. This approach targets tumor heterogeneity for more effective, less toxic treatments and aims to prevent cancer recurrence.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Cancer arises from accumulated genetic dysfunctions, leading to tumor heterogeneity and varied responses to chemotherapy, often resulting in recurrence.
- Traditional research focused on essential tumoral genes and driver mutations.
- Recent advancements leverage synthetic lethality (SL) interactions, inspired by PARP inhibitor success in specific cancer types.
Purpose of the Study:
- To review CRISPR screen methodology for identifying novel genetic interactions.
- To integrate current findings from CRISPR screens in cancer research.
- To propose future research directions for understanding cancer regulation and chemotherapy response.
Main Methods:
- Large-scale forward genetic CRISPR screens are the current state-of-the-art for discovering new genetic interactions.
- CRISPR technology is widely accessible and utilized in laboratories.
- This review synthesizes published data from CRISPR screens in the cancer field.
Main Results:
- CRISPR screens are powerful tools for uncovering synthetic lethality interactions (SLI).
- SLI enables the development of combinatorial therapies with potentially lower toxicity and higher efficiency.
- Understanding SLI is crucial for overcoming tumor heterogeneity and improving treatment outcomes.
Conclusions:
- CRISPR screens offer a robust platform for advancing cancer research and therapeutic strategies.
- Exploiting SLI through combinatorial therapies holds promise for more effective cancer treatment.
- Future research directions include further exploration of cancer regulation and personalized chemotherapy responses using CRISPR technology.
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
01:28CRISPR/Cas9 Genome Editing
01:59CRISPR
02:31Homologous Recombination
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...